Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Nemvaleukin Alfa Plus Pembrolizumab Gets Fast Track Status for Platinum-Resistant Ovarian Cancer

October 26th 2021

The FDA has granted a fast track designation to the interleukin-2 variant immunotherapy nemvaleukin alfa for use in combination with pembrolizumab in the treatment of patients with platinum-resistant ovarian cancer.

Dr. Secord on the Design of the OReO Trial in Ovarian Cancer

October 19th 2021

Angeles A. Secord, MD, discusses the design of the phase 3b OReO trial in ovarian cancer.

Bicycle Toxin Conjugates Showcase Early Activity and Tolerability in Urothelial, Ovarian Cancers

October 19th 2021

The bicycle toxin conjugates BT5528 and BT8009 have showcased preliminary signs of antitumor activity and encouraging tolerability when administered to patients with solid tumors such as urothelial cancer and ovarian cancer.

Dr. Lai on the Role of Maintenance Therapy and Secondary Cytoreduction in Ovarian Cancer

October 12th 2021

Tiffany S. Lai, MD, discusses the role of maintenance therapy and secondary cytoreduction in ovarian cancer.

Dr. Venkat on Treatment Considerations in Ovarian Cancer

October 11th 2021

Puja S. Venkat, discusses treatment considerations for patients with ovarian cancer.

Dr. Secord on Treatment Considerations in Platinum-Sensitive Ovarian Cancer

October 7th 2021

Angeles A. Secord, MD, discusses the individual therapeutic preferences and treatment considerations for patients with platinum-sensitive ovarian cancer.

Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer

October 7th 2021

Dr. Moore discusses the basis for studying the combination of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer, data that has been generated with the combination from the phase 1/2 FRAME trial, and the potential role for the combination in clinical practice.

Dr. Colombo on Practice-Changing KEYNOTE-826 Data in Metastatic Cervical Cancer

October 5th 2021

Nicoletta Colombo, MD, PhD, discusses efficacy achieved with the addition of pembrolizumab to chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer. 

Dr. Brown on the Clinical Implications of the PRIMA Trial in Ovarian Cancer

October 5th 2021

Jubilee Brown, MD, discusses the clinical implications of the phase 3 PRIMA trial in advanced ovarian cancer.

Dr. Salani on the Rationale for Immunotherapy/PARP Inhibitor Combos in Ovarian Cancer

October 4th 2021

Ritu Salani, MD, MBA, discusses the rationale for combinations of immunotherapy and PARP inhibitors in ovarian cancer.

Dr. Secord on Treating Patients with Platinum Sensitive Ovarian Cancer

October 1st 2021

Angeles A. Secord, MD, discusses treating patients with platinum-sensitive ovarian cancer.

Single-Agent and Combo Immunotherapy Garners Mixed Excitement in Gynecologic Cancers

September 30th 2021

Immunotherapy is emerging as a preferred second-line treatment option for patients with gynecologic cancers, including endometrial and cervical cancer. Checkpoint inhibitors may also be preferred to chemotherapy in the frontline or adjuvant settings based on improved efficacy.

Investigators Seek to Preserve Fertility in Ovarian Malignant Germ Cell Tumors

September 28th 2021

Germ cell tumors of the ovary are aggressive tumors derived from the primitive germ cells of the embryonic gonad and appear most often in young women or adolescent girls.

Dr. Backes on Challenges Regarding Staging of Ovarian Germ Cell Tumors

September 28th 2021

Floor J. Backes, MD, discusses challenges regarding staging and treatment locations in ovarian germ cell tumors.

Progress Moves Full Steam Ahead in Gynecologic Malignancies

September 27th 2021

Jubilee Brown, MD, contextualizes updates in endometrial cancer and cervical cancer, frontline and second-line maintenance, and novel immune-oncology combination strategies in ovarian cancer.

Dr. O’Malley on Balstilimab and Zalifrelimab in Recurrent/Metastatic Cervical Cancer

September 24th 2021

David M. O'Malley, MD, discusses future research directions with balstilimab and zalifrelimab in patients with cervical cancer.

Immunotherapy Combos, Novel Agents Hold Promise in Recurrent Ovarian Cancer

September 24th 2021

Ritu Salani, MD, MBA, discussed the clinical rationale to evaluate combination strategies with immunotherapy in ovarian cancer, as well as novel agents in clinical development that could further influence the treatment paradigm.

Dr. Salani on the Potential Impact of Ongoing Research in Ovarian Cancer

September 22nd 2021

Ritu Salani, MD, MBA, discusses the scope of ongoing research in advanced ovarian cancer.

Olaparib Rechallenge Improves PFS in Relapsed Ovarian Cancer Previously Treated With PARP Inhibition

September 17th 2021

Rechallenge with maintenance olaparib following response to platinum-based chemotherapy significantly improved progression-free survival in heavily pretreated patients with relapsed ovarian cancer, irrespective of BRCA status, according to results of the phase 3 OReO/ENGOT Ov-38 study.

Gynecologic Oncology Pioneer Franco Muggia Dies at 85

September 10th 2021

Franco Muggia, MD, a fixture at NYU Langone’s Perlmutter Cancer Center and a leader in the study and treatment of patients with gynecologic cancers, died on September 8, 2021. He was 85 years old.